Back to results
US 2024/0390367 A1Published application
Methods of treating vitiligo with upadacitinib
OwnerSumit Bhatnagar, Mohamed-Eslam F. Mohamed +1inventors
InventorsSumit Bhatnagar, Mohamed-Eslam F. Mohamed, Heidi S. Camp
Life of this patent
Estimating the term…
Abstract
The present disclosure is directed to methods for treating vitiligo using the selective JAK1 inhibitor upadacitinib.
Claims68
A method of treating an adult human patient having vitiligo, the method comprising orally administering once daily to the patient 15 mg of upadacitinib.
A method of treating vitiligo in a pediatric human patient, the method comprising administering a therapeutically effective amount of upadacitinib to the pediatric patient, wherein:
- if the pediatric patient has a body weight in a range from about 10 kg to less than about 20 kg:
- (i) the upadacitinib is administered twice daily at a dose of 3 mg each (3 mg BID), or
- (ii) the upadacitinib is administered twice daily at a dose of 6 mg each (6 mg BID);
- if the pediatric patient has a body weight in a range from about 20 kg to less than about 30 kg:
- (i) the upadacitinib is administered twice daily at a dose of 4 mg each (4 mg BID), or
- (ii) the upadacitinib is administered twice daily at a dose of 8 mg each (8 mg BID);
- and
- if the pediatric patient has a body weight of about 30 kg or greater:
- (i) the upadacitinib is administered twice daily at a dose of 6 mg each (6 mg BID),
- (ii) the upadacitinib is administered twice daily at a dose of 8 mg each (8 mg BID), or
- (ii) the upadacitinib is administered once daily at a dose of 15 mg (15 mg QD).
8 more elements
Dependencies are inferred from the claim text.